Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MT-5547 (Fasinumab) in osteoarthritis with moderate to severe pain
NCT03245008Phase 3Completed
- Sponsor
- Mitsubishi Tanabe Pharma
- Start
- Sep 2017
- Primary completion
- Dec 2019
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of fasinumab in osteoarthritis (OA) (3 arms), sponsored by Mitsubishi Tanabe Pharma. Primary endpoint: Western Ontario and McMaster Universities Osteoarthritis Index Pain at 16 weeks. Started Sep 2017; status: completed.
02
Drugs
fasinumab
03
Conditions
osteoarthritis (OA)
Beyond the preview
Go deeper on NCT03245008.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03245008.